Cutaneous T cell lymphoma expresses immunosuppressive CD80 (B7-1) cell surface protein in a stat5-dependent manner

Journal of Immunology

Volumn 192, Issue 6, 2014, Pages 2913-2919

  Zhang, Qian ^a   Wang, Hong Yi ^a   Wei, Fang ^a   Liu, Xiaobin ^a   Paterson, Jennifer C ^b   Roy, Darshan ^a   Mihova, Daniela ^a   Woetmann, Anders ^c   Ptasznik, Andrzej ^d   Odum, Niels ^c   Schuster, Stephen J ^a   Marafioti, Teresa ^b   Riley, James L ^a   Wasik, Mariusz A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; INTERLEUKIN 2; JANUS KINASE 1; JANUS KINASE 3; MESSENGER RNA; STAT5 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CD80 GENE; CELL VIABILITY; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE COMPLEX; GENE; GENE CONTROL; GENE INDUCTION; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; INTRACELLULAR SIGNALING; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFORMATION; LYMPHOMA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE SUBPOPULATION; TRANSCRIPTION INITIATION; TUMOR ESCAPE;

ADULT; ANTIGENS, CD80; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; CTLA-4 ANTIGEN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-2; JANUS KINASE 1; JANUS KINASE 3; LYMPHOMA, T-CELL, CUTANEOUS; MODELS, IMMUNOLOGICAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAT5 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; TUMOR SUPPRESSOR PROTEINS;

EID: 84897564116     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302951     Document Type: Article

References (25)

1. Hwang, S. T., J. E. Janik, E. S. Jaffe, and W. H. Wilson. 2008. Mycosis fungoides and Sézary syndrome. Lancet 371: 945-957.
2. Abraham, R. M., Q. Zhang, N. Odum, and M. A. Wasik. 2011. The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma. Cancer Biol. Ther. 12: 1019-1022.
3. Willerslev-Olsen, A., T. Krejsgaard, L. M. Lindahl, C. M. Bonefeld, M. A. Wasik, S. B. Koralov, C. Geisler, M. Kilian, L. Iversen, A. Woetmann, and N. Odum. 2013. Bacterial toxins fuel disease progression in cutaneous T-cell lymphoma. Toxins (Basel) 5: 1402-1421.
4. Chen, L., and D. B. Flies. 2013. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13: 227-242.
5. Ceeraz, S., E. C. Nowak, and R. J. Noelle. 2013. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol. 34: 556-563.
6. Greaves, P., and J. G. Gribben. 2013. The role of B7 family molecules in hematologic malignancy. Blood 121: 734-744.
7. Kasprzycka, M., Q. Zhang, A. Witkiewicz, M. Marzec, M. Potoczek, X. Liu, H. Y. Wang, M. Milone, S. Basu, J. Mauger, et al. 2008. Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes. J. Immunol. 181: 2506-2512.
8. Marzec, M., K. Halasa, M. Kasprzycka, M. Wysocka, X. Liu, J. W. Tobias, D. Baldwin, Q. Zhang, N. Odum, A. H. Rook, and M. A. Wasik. 2008. Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells. Cancer Res. 68: 1083-1091.
9. Zhang, Q., H. Y. Wang, X. Liu, and M. A. Wasik. 2007. STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression. Nat. Med. 13: 1341-1348.
10. Marzec, M., Q. Zhang, A. Goradia, P. N. Raghunath, X. Liu, M. Paessler, H. Y. Wang, M. Wysocka, M. Cheng, B. A. Ruggeri, and M. A. Wasik. 2008. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc. Natl. Acad. Sci. USA 105: 20852-20857.
11. Marzec, M., X. Liu, M. Kasprzycka, A. Witkiewicz, P. N. Raghunath, M. El-Salem, E. Robertson, N. Odum, and M. A. Wasik. 2008. IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes. Blood 111: 2181-2189.
12. Freedman, A. S., G. Freeman, J. C. Horowitz, J. Daley, and L. M. Nadler. 1987. B7, a B-cell-restricted antigen that identifies preactivated B cells. J. Immunol. 139: 3260-3267.
13. Yao, Z., Y. Kanno, M. Kerenyi, G. Stephens, L. Durant, W. T. Watford, A. Laurence, G. W. Robinson, E. M. Shevach, R. Moriggl, et al. 2007. Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood 109: 4368-4375.
14. Pentcheva-Hoang, T., J. G. Egen, K. Wojnoonski, and J. P. Allison. 2004. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 21: 401-413.
15. Vyth-Dreese, F. A., H. Boot, T. A. Dellemijn, D. M. Majoor, L. C. Oomen, J. D. Laman, M. Van Meurs, R. A. De Weger, and D. De Jong. 1998. Localization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin's lymphoma. Immunology 94: 580-586.
16. Chaperot, L., J. Plumas, M. C. Jacob, F. Bost, J. P. Molens, J. J. Sotto, and J. C. Bensa. 1999. Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkin's lymphomas. Exp. Hematol. 27: 479-488.
17. Dakappagari, N., S. N. Ho, R. D. Gascoyne, J. Ranuio, A. P. Weng, and S. Tangri. 2012. CD80 (B7.1) is expressed on both malignant B cells and nonmalignant stromal cells in non-Hodgkin lymphoma. Cytometry B Clin. Cytom. 82: 112-119.
18. Delabie, J., J. L. Ceuppens, P. Vandenberghe, M. de Boer, L. Coorevits, and C. De Wolf-Peeters. 1993. The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines. Blood 82: 2845-2852.
19. Leonard, J. P., J. W. Friedberg, A. Younes, D. Fisher, L. I. Gordon, J. Moore, M. Czuczman, T. Miller, P. Stiff, B. D. Cheson, et al. 2007. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann. Oncol. 18: 1216-1223.
20. Smith, S. M., H. Schöder, J. L. Johnson, S. H. Jung, N. L. Bartlett, and B. D. Cheson; Alliance for Clinical Trials in Oncology. 2013. The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). Leuk. Lymphoma 54: 1405-1410.
21. Ansell, S. M., S. A. Hurvitz, P. A. Koenig, B. R. LaPlant, B. F. Kabat, D. Fernando, T. M. Habermann, D. J. Inwards, M. Verma, R. Yamada, et al. 2009. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin. Cancer Res. 15: 6446-6453.
22. Hodi, F. S., S. J. O'Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J. C. Hassel, et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363: 711-723.
23. Krejsgaard, T., I. V. Litvinov, Y. A. Wang, L. Xia, A. Willerslev-Olsen, S. B. Koralov, K. L. Kopp, C. M. Bonefeld, M. A. Wasik, C. Geisler, et al. 2013. Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma. Blood 122: 943-950.
24. Kantekure, K., Y. Yang, P. Raghunath, A. Schaffer, A. Woetmann, Q. Zhang, N. Odum, and M. A. Wasik. 2012. Expression patterns of the immunosuppressive proteins PD-1/CD279 and PD-L1/CD274 at different stages of cutaneous T-cell lymphoma/mycosis fungoides. Am. J. Dermatopathol. 34: 126-128.
25. Zhang, Q., H. Wang, K. Kantekure, J. C. Paterson, X. Liu, A. Schaffer, C. Paulos, M. C. Milone, N. Odum, S. Turner, et al. 2011. Oncogenic tyrosine kinase NPM-ALK induces expression of the growth-promoting receptor ICOS. Blood 118: 3062-3071.